Oxidation‑reduction potential parameters worsen following intraarterial therapy in patients with reduced collateral circulation and middle cerebral artery occlusions.
MCA occlusion
ORP
collateral circulation
Journal
Experimental and therapeutic medicine
ISSN: 1792-1015
Titre abrégé: Exp Ther Med
Pays: Greece
ID NLM: 101531947
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
22
07
2022
accepted:
24
03
2023
medline:
25
5
2023
pubmed:
25
5
2023
entrez:
25
5
2023
Statut:
epublish
Résumé
Collateral circulation is important for cerebral perfusion in acute ischemic strokes. Monitoring the oxidation-reduction potential (ORP) may be useful to assess collateral status or treatment efficacy. The objectives of the present study were to determine if the ORP was associated with collateral circulation status in middle cerebral artery (MCA) occlusions and to identify patterns in the ORP and the collateral circulation status among patients treated with intraarterial therapy (IAT) over time. The present pilot study was nested within a prospective cohort study measuring the ORP of the peripheral venous plasma of stroke patients. The population included in the present study were patients with MCA (M1/M2) occlusions. Two ORP parameters were examined: Static ORP (sORP; mV), indicating oxidative stress, and capacity ORP (cORP; µC), indicating antioxidant reserves. Collateral status was retrospectively graded using Miteff's system as good (grade 1) or reduced (grade 2/3). Comparisons were made between collateral status groups (reduced vs. good collaterals) in all patients, within a subset including only patients who received IAT, and between thrombolysis in cerebral infraction scale score (TICI) groups (0-2a vs. 2b/3). The Fisher's exact test, Student's t-test and Wilcoxon tests were used (α<0.20). The 19 patients were categorized based on their collaterals: Good collaterals (53%) and reduced collaterals (47%). The baseline characteristics were similar with the exception that the patients with good collaterals had a lower international normalized ratio (P=0.12) and were more likely to have a stroke on the left side (P=0.18) or to have a mismatch (P=0.05). The admission sORP values were comparable (169.5 vs. 164.2 mV; P=0.65), as was admission cORP (P=0.73). When considering only the patients who received IAT (n=12), admission sORP (P=0.69) and cORP (P=0.90) were also statistically similar. On day 2, after IAT, both groups experienced a worsening in ORP measures; however, the patients with good collaterals had a significantly lower sORP (169.4 vs. 203.5 mV; P=0.02) and a higher cORP (0.2 vs. 0.1 µC; P=0.002) compared with the patients with reduced collaterals. Neither sORP nor cORP were significantly different between TICI score groups on admission or on day 2. Upon discharge, patients with a TICI of 2b-3 had a significantly better sORP (P=0.03) and cORP (P=0.12) compared with those with a TICI of 0-2a. In conclusion, upon patient admission, the ORP parameters were not significantly different between the collateral circulation status groups for MCA occlusions. The ORP parameters worsened after IAT regardless of the collateral circulation status; however, after IAT, on day 2, patients with good collaterals experienced less oxidative stress (sORP) and had higher antioxidant reserves (cORP) than patients with reduced collaterals.
Identifiants
pubmed: 37229324
doi: 10.3892/etm.2023.11994
pii: ETM-25-6-11994
pmc: PMC10203750
doi:
Types de publication
Journal Article
Langues
eng
Pagination
295Informations de copyright
Copyright: © Atchie et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Neurosci Bull. 2014 Apr;30(2):271-81
pubmed: 24664866
Sci Rep. 2021 Oct 22;11(1):20942
pubmed: 34686696
Clin Interv Aging. 2007;2(1):147-51
pubmed: 18044087
Oxid Med Cell Longev. 2018 Jan 31;2018:9719584
pubmed: 29643982
Injury. 2021 Oct;52(10):2908-2913
pubmed: 33573809
Curr Hypertens Rev. 2015;11(2):132-42
pubmed: 26022210
Pharm Stat. 2011 Jul-Aug;10(4):363-8
pubmed: 21140524
Cell Stress Chaperones. 2019 Mar;24(2):441-452
pubmed: 30815818
Stroke. 2015 May;46(5):1239-44
pubmed: 25791716
Exp Ther Med. 2018 Jan;15(1):707-718
pubmed: 29399075
Int J Prev Med. 2017 Sep 14;8:70
pubmed: 28983399
Oxid Med Cell Longev. 2016;2016:6974257
pubmed: 27642494
Stroke. 2004 Aug;35(8):1908-13
pubmed: 15205487
J Neurointerv Surg. 2016 Nov;8(11):1116-1118
pubmed: 26658280
AJNR Am J Neuroradiol. 2011 May;32(5):864-8
pubmed: 21310859
Int J Radiat Oncol Biol Phys. 1980 Mar;6(3):371-4
pubmed: 7390914
Stroke. 2010 Nov;41(11):2661-8
pubmed: 20947850
Stroke. 2003 Aug;34(8):e109-37
pubmed: 12869717
Perfusion. 2014 Sep;29(5):450-5
pubmed: 24534888
Chest. 2013 Jul;144(1):266-273
pubmed: 23880677
Int J Mol Sci. 2016 Aug 29;17(9):
pubmed: 27589720
J Neurol Neurosurg Psychiatry. 2008 Jun;79(6):625-9
pubmed: 18077482
Free Radic Biol Med. 2020 Aug 1;155:29-36
pubmed: 32450129
Stroke. 2003 Sep;34(9):2279-84
pubmed: 12881609
CNS Neurosci Ther. 2019 Dec;25(12):1353-1362
pubmed: 31793209
Front Neurol. 2019 Jul 02;10:709
pubmed: 31312177
JAMA Neurol. 2021 Aug 1;78(8):916-926
pubmed: 34125153
Int J Cardiol. 2007 Mar 2;116(1):14-9
pubmed: 16824626
J Neuroinflammation. 2020 Nov 27;17(1):361
pubmed: 33246465
World Neurosurg. 2022 Sep;165:e128-e136
pubmed: 35680084
J Cereb Blood Flow Metab. 2017 Nov;37(11):3589-3598
pubmed: 27864462
Brain. 2009 Aug;132(Pt 8):2231-8
pubmed: 19509116
Nutr Rev. 2000 Jun;58(6):184-7
pubmed: 10885327
Stroke. 2014 Jul;45(7):2036-40
pubmed: 24876081
Pilot Feasibility Stud. 2021 Feb 3;7(1):40
pubmed: 33536076
Redox Biol. 2015;4:340-5
pubmed: 25644686
Stroke. 2019 Dec;50(12):3456-3464
pubmed: 31619153
Stat Med. 2012 May 20;31(11-12):1031-42
pubmed: 22052407
Exp Ther Med. 2016 Mar;11(3):895-903
pubmed: 26998009
Stroke. 2014 Apr;45(4):1035-9
pubmed: 24569816